Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Sales of drugs within the psoriasis sector to be worth $7.4 billion by 2020

Industry Sector

Healthcare and Medical


17 April 2013


Matt Bodimeade

Type of News


The psoriasis market experienced approximately 36.5 million prevalent cases across the US, France, Germany, Italy, Spain, UK, Japan, China, and India in 2012. By 2022, epidemiologists forecast that this figure will reach approximately 40.93 million cases, following a 12.1% increase based on projected population growth.

Psoriasis is an immune-mediated disease that affects the skin. It is typically a lifelong condition. There is currently no cure, but various treatments can help to control the symptoms.

Psoriasis occurs when the immune system mistakes a normal skin cell for a pathogen, and sends out faulty signals that cause overproduction of new skin cells. Psoriasis is not contagious. However, psoriasis has been linked to an increased risk of stroke, and treating high blood lipid levels may lead to improvement.

Psoriasis is an autoimmune disorder, so family history plays an important role in the development of the disease. Approximately 40% of psoriasis patients have first-degree relatives with the disease. Since psoriasis is categorised as an immune-mediated inflammatory disorder (IMFD), sufferers are also at an increased risk of developing other, more severe IMFDs, such as rheumatoid arthritis and Crohn's disease.

Sales of drugs to treat psoriasis across seven major markets have been forecast to increase from a value of $3.9 billion in 2010 to more than $7.4 billion by 2020.

Market growth will be driven by the continued uptake of Janssen Biotech/Janssen Cilag's Stelara (ustekinumab) and Abbott/Eisai's Humira (adalimumab), plus the launch and prescribing of two emerging therapies - Pfizer's tofacitinib and Novartis' secukinumab.

Amgen/Steifel/Pfizer/Takeda's Enbrel (etanercept) maintained its market dominance last year, earning $1.3 billion in sales for the treatment of psoriasis, but this drug will face stiff competition from Humira, Stelara and secukinumab over the coming years.

These premium-priced agents are expected to replace less effective existing treatments and drive a rapid increase in sales of therapies for moderate-to-severe disease, which will account for the overwhelming majority of the psoriasis market in 2020.

For more information on the psoriasis market, see the latest research: Psoriasis Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency


Change Currency


Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.


Contrast settings

Text size settings